Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (121 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-03-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancermg dlfunction000mm3
  Phrases that lowered it: symptomspatients whoclinicalgroupevaluation of
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 58 (lowers risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 13.6% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 98.3% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 80 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 106 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients NCT05351021 · started 2022 · scored riskier than 10% of active trials completed
• Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel NCT02297412 · started 2014 · scored riskier than 63% of active trials completed
• Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients NCT05189535 · started 2021 · scored riskier than 18% of active trials completed
• Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer NCT02468739 · started 2015 · scored riskier than 14% of active trials completed
• A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity NCT04222790 · started 2020 · scored riskier than 80% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.